Prostate Cancer Study Decision Tree

Patients with mCRPC who have progressed on a previous ARPI will be randomized 2:1 to SOC + TLX-591 vs SOC alone. SOC will be either ARPI switch or Docetaxel. TLX-591 is a radioligand therapy using Lutitium Rosopatamb, which is an antibody drug conjugate.

A Phase 2 Study of JNJ-78278343, a RIPTAC® Therapy, in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)